Effects of long-term treatment with suloctidil on blood viscosity, erythrocyte deformability and total fibrinogen plasma levels in diabetic patients.

1-(4-Isopropylthiophenyl)-2-n-octylaminopropanol (suloctidil, Sulocton), a drug introduced into clinical practice for the treatment of cerebral and peripheral vascular insufficiency and its complications, has been shown to decrease blood hyperviscosity after long-term treatment in diabetic patients. Suloctidil was particularly effective in lowering measured blood viscosity at high shear rate (230 s-1). At low shear rate (0.

Effects of suloctidil on lipid metabolism in experimental animals.

A novel potent vasoactive agent, 1-(4-isopropyl-thiophenyl)-2-n-octylaminopropanol (suloctidil, Sulocton), lowers excess of plasma cholesterol and tends to normalize the plasma hyperbetalipoproteinemia of Rhesus monkeys fed a high-cholesterol, high-fat diet. The drug shows an inhibitory effect on the cholesterol biosynthesis in rat liver homogenates.

Antiplatelet and antithrombogenic effects of suloctidil.

Platelet aggregation induced in mice or rats by i.v. ADP can be antagonized by oral administration of suloctidil.

In vivo antispasmodic activity of Sulcotidil.

Suloctidil was tested in vivo for its antispasmodic activity on peripheral and cerebral circulations. In the perfused dog hind limb preperation, suloctidil was found to inhibit after 2 and 5 min, the vasospasm induced by norepinephrine or angiotensin; at equal dose, and at the game time intervals, it was more potent than cinnarizine and papaverine. BaCl(2) induced spasms of the pial arterial of the rabbit were also rapidly alleviated by i.